Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

High Response Rate to Carboplatin-Paclitaxel-Cetuximab and Pembrolizumab in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

High Response Rate to Carboplatin-Paclitaxel-Cetuximab and Pembrolizumab in Patients with... The management of R/M HNSCC is rapidly evolving with new available treatment molecules and combination modalities. Anti-EGFR cetuximab (CTX) and immune checkpoint inhibitors (ICI) can be used either alone or in combination with conventional platinum-based doublet chemotherapy (with taxanes or fluorouracil). No data have been reported to date on the association of doublet chemotherapy concomitantly with both CTX and ICI. We present a case series of patients treated with 4 cycles of quadritherapy, every 3 weeks, including paclitaxel 175 mg/m<sup>2</sup>, carboplatin AUC 5, pembrolizumab 200 mg, and weekly 250 mg/m<sup>2</sup> CTX. All patients achieved an objective response (6 complete responses, 2 partial responses). Clinical response was fast, so 1 patient avoided an emergency tracheostomy for laryngeal dyspnea. Four patients furtherly benefited from cisplatin-based chemoradiotherapy on residual tumor sites after the response to quadritherapy. Adverse events were manageable, except for an ICI-related liver toxicity in a patient. Overall, this short series indicates that a quadruple therapy with carboplatin-paclitaxel-CTX and pembrolizumab seems to be safe and active in patients with R/M HNSCC. This observation could be confirmed through further clinical trials. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Case Reports in Oncology Karger

High Response Rate to Carboplatin-Paclitaxel-Cetuximab and Pembrolizumab in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

Download PDF
8 pages

Loading next page...
 
/lp/karger/high-response-rate-to-carboplatin-paclitaxel-cetuximab-and-QOLJrNMK0g
Publisher
Karger
Copyright
© 2023 The Author(s). Published by S. Karger AG, Basel
eISSN
1662-6575
DOI
10.1159/000528326
Publisher site
See Article on Publisher Site

Abstract

The management of R/M HNSCC is rapidly evolving with new available treatment molecules and combination modalities. Anti-EGFR cetuximab (CTX) and immune checkpoint inhibitors (ICI) can be used either alone or in combination with conventional platinum-based doublet chemotherapy (with taxanes or fluorouracil). No data have been reported to date on the association of doublet chemotherapy concomitantly with both CTX and ICI. We present a case series of patients treated with 4 cycles of quadritherapy, every 3 weeks, including paclitaxel 175 mg/m<sup>2</sup>, carboplatin AUC 5, pembrolizumab 200 mg, and weekly 250 mg/m<sup>2</sup> CTX. All patients achieved an objective response (6 complete responses, 2 partial responses). Clinical response was fast, so 1 patient avoided an emergency tracheostomy for laryngeal dyspnea. Four patients furtherly benefited from cisplatin-based chemoradiotherapy on residual tumor sites after the response to quadritherapy. Adverse events were manageable, except for an ICI-related liver toxicity in a patient. Overall, this short series indicates that a quadruple therapy with carboplatin-paclitaxel-CTX and pembrolizumab seems to be safe and active in patients with R/M HNSCC. This observation could be confirmed through further clinical trials.

Journal

Case Reports in Oncology – Karger

Published: Jan 1, 2023

Keywords: Cetuximab; Pembrolizumab; Paclitaxel; Carboplatin; Head and neck squamous cell carcinoma

References

  • Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Machiels, JP; René Leemans, C; Golusinski, W; Grau, C; Licitra, L; Gregoire, V
  • Platinum-based chemotherapy plus cetuximab in head and neck cancer
    Vermorken, JB; Mesia, R; Rivera, F; Remenar, E; Kawecki, A; Rottey, S
  • Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial
    Guigay, J; Aupérin, A; Fayette, J; Saada-Bouzid, E; Lafond, C; Taberna, M
  • Randomized phase II study with cetuximab in combination with 5-FU and cisplatin or carboplatin versus. cetuximab in combination with paclitaxel and carboplatin for treatment of patients with relapsed or metastatic squamous cell carcinoma of the head and neck (CETMET trial)
    Tsakonas, G; Specht, L; Kristensen, CA; Moreno, MHC; Cange, HH; Soderstrom, K
  • Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02)
    Tahara, M; Kiyota, N; Yokota, T; Hasegawa, Y; Muro, K; Takahashi, S
  • Efficacy and feasibility of induction chemotherapy with paclitaxel, carboplatin and cetuximab for locally advanced unresectable head and neck cancer patients ineligible for combination treatment with docetaxel, cisplatin, and 5-fluorouracil
    Shirasu, H; Yokota, T; Kawakami, T; Hamauchi, S; Onozawa, Y; Ogawa, H
  • Weekly paclitaxel, carboplatin, and cetuximab as first-line treatment of recurrent and/or metastatic head and neck squamous cell carcinoma for patients ineligible to cisplatin-based chemotherapy: a retrospective monocentric study in 60 patients
    Carinato, H; Burgy, M; Ferry, R; Fischbach, C; Kalish, M; Guihard, S
  • Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
    Burtness, B; Harrington, KJ; Greil, R; Soulières, D; Tahara, M; de Castro, G
  • Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial
    Sacco, AG; Chen, R; Worden, FP; Wong, DJL; Adkins, D; Swiecicki, P
  • Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial
    Della Corte, CM; Fasano, M; Ciaramella, V; Cimmino, F; Cardnell, R; Gay, CM